Comparing clinical chemistry analyzers for procurement requires separating documented performance from commercial positioning. The practical approach is to anchor a comparison in three linked decision areas: whether the instrument matches laboratory volume without hidden operational constraints; whether results remain comparable across platforms through formal verification; and whether priced cost per test actually reflects calibration, service, and consumable loading. Vendor materials provide several starting points, but they are incomplete on their own. A documented procurement comparison therefore treats manufacturer specifications as claims to be checked against independent evaluations [1][2][3]. The sections below describe specific decision points and show how a buyer might structure one concrete, labeled example without fabricating performance data.
Throughput claims must be matched to a realistic workload
Manufacturer documentation for the Beckman Coulter AU5800 series illustrates how throughput is segmented rather than expressed as a single number. The AU5810 lists photometric throughput up to 2,000 tests per hour, rising to 3,800 with dual ISE; the AU5820 lists up to 4,000 photometric tests per hour and 5,800 with dual ISE [1]. Onboard reagent capacity also scales, from 54 reagents on the AU5810 to 108 on the AU5820 and 162 on the AU5830 [1]. The manufacturer also ties each model to an annual test volume range for hospital or reference laboratories [1].
A health system comparing these analyzers should not treat the highest advertised figure as a routine deliverable. Photometric and ISE throughput are separate measures; the larger number depends on ion-selective electrode processing, which may not apply to every menu selection. Volume ranges published by the vendor can help eliminate an obvious mismatch, but procurement still needs to calculate a daily peak workload based on the ordering patterns in the specific laboratory. Vendor statements do not confirm that any particular test mix will achieve the headline rate.
Multi-instrument comparability is a formal verification problem
A meaningful comparison across vendors often follows from a specific comparability study, but the conclusions are narrow. One evaluation compared Roche Cobas 8000 and Mindray BS2000M for correlation and consistency across selected biomarkers [2]. For several analytes, including CK, LDH-1, RBP, Cys-C, IgM, and IgG, the authors considered the two instruments interchangeable, while other markers showed weaker agreement or linearity limitations [2]. One anchor reports correlation coefficients above 0.91 except for IgA, with IgA itself at approximately 0.851, and manufacturer-claimed linearity ranges not confirmed for some other analytes [2]. These conclusions apply only to the measured panel and this specific instrument pairing.
Larger networks face an additional challenge when multiple models from different manufacturers report for overlapping patient populations. A five-year evaluation across five instruments at one healthcare center used the Beckman Coulter AU5800 as the comparative system and applied conversion factors when results fell outside allowable ranges [4]. Approximately 58% of results required conversion due to non-comparable verification, and the laboratory reported the results after applying linear regression-based conversion [4]. Such a process is an operational commitment, not a one-time instrument feature. It requires residual patient samples, weekly verification, and periodic simplified comparisons [4].
Shortlist worksheet
A specific comparison exercise should tabulate, for each candidate: advertised throughput with and without ISE, onboard reagent positions, target annual test volume range [1][6]; listed price and first US sale year from CAP TODAY product guide entries [7][8]; calibration frequency and whether the per-test figure includes service [3]; and a boundary condition for acceptable local bias against the incumbent analyzer [4]. For each independent evaluation, record the study pair, analyte panel, funding source, and whether reference interval verification was performed [5].
Reagent rental pricing needs a cost per reportable test calculation
Contracts can be compared only when consumables, calibration, and support are loaded into a common financial unit. A procurement analysis for a biochemistry analyzer on a maintenance-free reagent rental basis described a cost per reportable test that included calibration and assumed electricity backup costs within the per-test rate [3]. The study reported that the cost per reportable test under that basis was 47.4% lower than the prior cost per test for purchased equipment [3]. The authors described the approach as a way to make bids comparable across analyzers with uniform cost inclusion [3].
The key procurement decision point is calibration frequency. In the reported analysis, calibration occurred on average once per hundred tests, and that requirement was used to distribute calibration cost into the per-test figure [3]. A buyer cannot assume every instrument follows that pattern. A comparison model should require each bidder to list calibration cadence, number of measured parameters, and whether service is maintenance-free. The 47.4% reduction in one institution's cost exercise does not generalize to a market-wide conclusion; it demonstrates a method rather than a universal price difference [3].
Independent analytical evaluations add a narrow but useful layer
Manufacturer documentation often points to clinical evaluations, but these evaluations carry limitations that procurement teams should read carefully. A published evaluation of the Siemens Atellica CI Analyzer assessed 17 analytes over three months in a European laboratory setting, using remnant serum samples for precision and method comparison against the Roche cobas 6000 [5]. The authors reported coefficients of variation below 2% for repeatability and below 3% for within-laboratory imprecision for most analytes, and correlation coefficients from 0.980 to 1.000 for selected assays [5]. The evaluation received funding from Siemens Healthcare Diagnostics Inc. [5].
The study's own authors describe the work as the first reported evaluation in a clinical laboratory setting, and they state that reference intervals were not verified for each assay and that workflow efficiency claims would need separate studies [5]. For procurement, this kind of evidence supports a decision to place the instrument on a shortlist, not a decision to ignore method comparison at the purchasing site. A comparison matrix should therefore reserve weight for independent evaluations while requiring local correlation testing against the incumbent analyzer before final acceptance.
A labeled comparison example for a hypothetical mid-volume laboratory
The following is a suggested structure, not a description of an actual purchasing event. Suppose a hospital laboratory expects a mid-volume workload and is choosing between the Beckman Coulter DxC 700 AU, positioned as a mid-volume system, and a comparable combination chemistry and immunoassay platform such as an Alinity ci-series configuration or cobas 6000 series [6][8]. The procurement team would first calculate the relevant weekly test count and compare it with the throughput and onboard reagent capacity for each option rather than relying on manufacturer volume labels.
The comparison would then require parallel financial and analytical submissions. On the financial side, the team would ask each bidder for a cost per reportable test that includes calibration, consumables, and service, with calibration cadence stated. On the analytical side, the team would require a local method comparison against the existing instrument for the top 10 ordered analytes, using residual patient samples and an allowable bias threshold. The evaluation would not declare a winning instrument; instead, it would expose where the two options differ in calibration frequency, monthly support cost, and reported bias.
Sources & references
- AU5800 Series Chemistry Analyzers | Beckman Coulter · www.beckmancoulter.com
- Performance evaluation between two automated biochemical analyzer systems: Roche Cobas 8000 and Mindray BS2000M · pmc.ncbi.nlm.nih.gov
- An Approach to Include the Cost of Consumables in Biochemistry Analyzer Procurement on the Reagent Rental Model Alleviates Hidden Expenses - PMC · pmc.ncbi.nlm.nih.gov
- Periodic Comparability Verification and Within-Laboratory Harmonization of Clinical Chemistry Laboratory Results at a Large Healthcare Center With Multiple Instruments - PMC · pmc.ncbi.nlm.nih.gov
- Analytical performance evaluation of a new integrated clinical chemistry and immunoassay analyzer - PMC · pmc.ncbi.nlm.nih.gov
- Clinical Chemistry Analyzers and Assays | Beckman Coulter · www.beckmancoulter.com
- CHEMISTRY AND IMMUNOASSAY ANALYZERS · www.captodayonline.com
- [PDF] CHEMISTRY AND IMMUNOASSAY ANALYZERS - cap today · www.captodayonline.com